- Home
- CTNM vs ALT Comparison
CTNM vs ALT Comparison
Compare CTNM & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTNM | ALT |
|---|---|---|
| Founded | 2009 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.0M | 415.3M |
| IPO Year | 2024 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CTNM | ALT |
|---|---|---|
| Price | $13.36 | $3.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $19.00 | $17.67 |
| AVG Volume (30 Days) | 322.2K | ★ 2.9M |
| Earning Date | 03-05-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 0.46 | ★ 25.37 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $3.35 | $2.91 |
| 52 Week High | $16.33 | $7.73 |
Technical Indicators
Market Signals| Indicator | CTNM | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 36.44 |
| Support Level | $10.39 | $2.91 |
| Resistance Level | $15.80 | $4.25 |
| Average True Range (ATR) | 1.11 | 0.19 |
| MACD | -0.13 | -0.01 |
| Stochastic Oscillator | 44.00 | 15.90 |
Price Performance
Historical ComparisonAbout CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.